Office of National Drug Control Policy bannerskip
skip tertiary linksHome | About | Site Map | Contact

Press Release

FOR IMMEDIATE RELEASE
Contact: Tom Riley / Brian Blake (202) 395–6618

April 22, 2002

DEPUTY DIRECTOR OF ONDCP
CONFIRMED BY U.S. SENATE

MARY ANN SOLBERG TO BRING HER COMMUNITY COALITION AND DRUG PREVENTION EXPERTISE TO DRUG CZAR'S OFFICE

(Washington, D.C.)–Today the United States Senate confirmed Mary Ann Solberg as Deputy Director of the Office of National Drug Control Policy (ONDCP). Mrs. Solberg's extensive experience working with community anti-drug coalitions at the grassroots level will greatly benefit ONDCP's efforts to reduce drug use in America.

John P. Walters, the Director of National Drug Control Policy, said, "Over the course of her career, Mary Ann Solberg has been a leading innovator in the community drug-prevention movement. Her advocacy has had a positive impact on tens of thousands of young people. Mary Ann's expertise and experience will be a tremendous asset in our efforts to reduce substance abuse."

Prior to joining ONDCP, Mrs. Solberg served in Michigan as the Executive Director of both the Troy Community Coalition for the Prevention of Drug and Alcohol Abuse and the Coalition of Healthy Communities. Her expertise is solicited by community coalitions all across the United States. She travels extensively as a lecturer and consultant helping communities form prevention coalitions and providing technical assistance to community partnerships and coalitions. She also serves as an advisor to the Department of Health and Human Services' Center for Substance Abuse Prevention and as a member of the Board of Directors of the Community Anti-Drug Coalitions of America.

Blog News

More Blog News

Subscribe to RSS Feed

ONDCP provides a number of RSS feeds that provide updates on a variety of drug related issues.

Mobile Web

You can access the most newsworthy sections of the ONDCP Web site from handheld computers and Internet-enabled wireless phones.

ONDCP's Mobile Web


The Anti-Drug logo



skip navigationInformation Quality Guidelines | Privacy Policy | Site Map | Disclaimer | Accessibility | FOIA